FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225142419> ?p ?o ?g. }

• W4225142419 endingPage "506.e12" @default.
• W4225142419 startingPage "506.e1" @default.
• W4225142419 abstract "BackgroundMaternal alloantibodies to human platelet antigen-1a can cause severe intracranial hemorrhage in a fetus or newborn. Although never evaluated in placebo-controlled clinical trials, most Western countries use off-label weekly administration of high-dosage intravenous immunoglobulin in all pregnant women with an obstetrical history of fetal and neonatal alloimmune thrombocytopenia. In Norway, antenatal intravenous immunoglobulin is only recommended in pregnancies wherein a previous child had intracranial hemorrhage (high-risk) and is generally not given in other human platelet antigen-1a alloimmunized pregnancies (low-risk).ObjectiveTo compare the frequency of anti-human platelet antigen-1a-induced intracranial hemorrhage in pregnancies at risk treated with intravenous immunoglobulin vs pregnancies not receiving this treatment as a part of a different management program.Study DesignThis was a retrospective comparative study where the neonatal outcomes of 71 untreated human platelet antigen-1a-alloimmunized pregnancies in Norway during a 20-year period was compared with 403 intravenous-immunoglobulin-treated pregnancies identified through a recent systematic review. We stratified analyses on the basis of whether the mothers belonged to high- or low-risk pregnancies. Therefore, only women who previously had a child with fetal and neonatal alloimmune thrombocytopenia were included.ResultsTwo neonates with brain bleeds were identified from 313 treated low-risk pregnancies (0.6%; 95% confidence interval, 0.2–2.3). There were no neonates born with intracranial hemorrhage of 64 nontreated, low-risk mothers (0.0%; 95% confidence interval, 0.0–5.7). Thus, no significant difference was observed in the neonatal outcome between immunoglobulin-treated and untreated low-risk pregnancies. Among high-risk mothers, 5 of 90 neonates from treated pregnancies were diagnosed with intracranial hemorrhage (5.6%; 95% confidence interval, 2.4–12.4) compared with 2 of 7 neonates from nontreated pregnancies (29%; 95% confidence interval, 8.2–64.1; P=.08).ConclusionThe most reliable data hitherto for the evaluation of intravenous immunoglobulins treatment in low-risk pregnancies is shown herein. We did not find evidence that omitting antenatal intravenous immunoglobulin treatment in low-risk pregnancies increases the risk of neonatal intracranial hemorrhage. Maternal alloantibodies to human platelet antigen-1a can cause severe intracranial hemorrhage in a fetus or newborn. Although never evaluated in placebo-controlled clinical trials, most Western countries use off-label weekly administration of high-dosage intravenous immunoglobulin in all pregnant women with an obstetrical history of fetal and neonatal alloimmune thrombocytopenia. In Norway, antenatal intravenous immunoglobulin is only recommended in pregnancies wherein a previous child had intracranial hemorrhage (high-risk) and is generally not given in other human platelet antigen-1a alloimmunized pregnancies (low-risk). To compare the frequency of anti-human platelet antigen-1a-induced intracranial hemorrhage in pregnancies at risk treated with intravenous immunoglobulin vs pregnancies not receiving this treatment as a part of a different management program. This was a retrospective comparative study where the neonatal outcomes of 71 untreated human platelet antigen-1a-alloimmunized pregnancies in Norway during a 20-year period was compared with 403 intravenous-immunoglobulin-treated pregnancies identified through a recent systematic review. We stratified analyses on the basis of whether the mothers belonged to high- or low-risk pregnancies. Therefore, only women who previously had a child with fetal and neonatal alloimmune thrombocytopenia were included. Two neonates with brain bleeds were identified from 313 treated low-risk pregnancies (0.6%; 95% confidence interval, 0.2–2.3). There were no neonates born with intracranial hemorrhage of 64 nontreated, low-risk mothers (0.0%; 95% confidence interval, 0.0–5.7). Thus, no significant difference was observed in the neonatal outcome between immunoglobulin-treated and untreated low-risk pregnancies. Among high-risk mothers, 5 of 90 neonates from treated pregnancies were diagnosed with intracranial hemorrhage (5.6%; 95% confidence interval, 2.4–12.4) compared with 2 of 7 neonates from nontreated pregnancies (29%; 95% confidence interval, 8.2–64.1; P=.08). The most reliable data hitherto for the evaluation of intravenous immunoglobulins treatment in low-risk pregnancies is shown herein. We did not find evidence that omitting antenatal intravenous immunoglobulin treatment in low-risk pregnancies increases the risk of neonatal intracranial hemorrhage." @default.
• W4225142419 created "2022-05-01" @default.
• W4225142419 creator A5029124921 @default.
• W4225142419 creator A5034598092 @default.
• W4225142419 creator A5049560724 @default.
• W4225142419 creator A5053296449 @default.
• W4225142419 creator A5067132709 @default.
• W4225142419 creator A5073825416 @default.
• W4225142419 date "2022-09-01" @default.
• W4225142419 modified "2023-09-30" @default.
• W4225142419 title "Antenatal intravenous immunoglobulins in pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia: comparison of neonatal outcome in treated and nontreated pregnancies" @default.
• W4225142419 cites W106013536 @default.
• W4225142419 cites W1557479152 @default.
• W4225142419 cites W1972391546 @default.
• W4225142419 cites W1974802007 @default.
• W4225142419 cites W1978671391 @default.
• W4225142419 cites W1982320298 @default.
• W4225142419 cites W1982719407 @default.
• W4225142419 cites W1983617632 @default.
• W4225142419 cites W1991198699 @default.
• W4225142419 cites W2009463326 @default.
• W4225142419 cites W2021867113 @default.
• W4225142419 cites W2028055828 @default.
• W4225142419 cites W2029536644 @default.
• W4225142419 cites W2041879870 @default.
• W4225142419 cites W2042259959 @default.
• W4225142419 cites W2043308724 @default.
• W4225142419 cites W2044052575 @default.
• W4225142419 cites W2048804351 @default.
• W4225142419 cites W2061838561 @default.
• W4225142419 cites W2064325270 @default.
• W4225142419 cites W2064363923 @default.
• W4225142419 cites W2065163701 @default.
• W4225142419 cites W2088854701 @default.
• W4225142419 cites W2105033197 @default.
• W4225142419 cites W2105445079 @default.
• W4225142419 cites W2110320870 @default.
• W4225142419 cites W2127556149 @default.
• W4225142419 cites W2144840345 @default.
• W4225142419 cites W2146272590 @default.
• W4225142419 cites W2150588741 @default.
• W4225142419 cites W2168348906 @default.
• W4225142419 cites W2168748148 @default.
• W4225142419 cites W2171075705 @default.
• W4225142419 cites W2266005602 @default.
• W4225142419 cites W2414436823 @default.
• W4225142419 cites W2583039933 @default.
• W4225142419 cites W2757072329 @default.
• W4225142419 cites W2904983456 @default.
• W4225142419 cites W2919311410 @default.
• W4225142419 cites W2997767677 @default.
• W4225142419 cites W3031193582 @default.
• W4225142419 cites W3044417209 @default.
• W4225142419 cites W3142603720 @default.
• W4225142419 cites W83303467 @default.
• W4225142419 doi "https://doi.org/10.1016/j.ajog.2022.04.044" @default.
• W4225142419 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35500612" @default.
• W4225142419 hasPublicationYear "2022" @default.
• W4225142419 type Work @default.
• W4225142419 citedByCount "6" @default.
• W4225142419 countsByYear W42251424192022 @default.
• W4225142419 countsByYear W42251424192023 @default.
• W4225142419 crossrefType "journal-article" @default.
• W4225142419 hasAuthorship W4225142419A5029124921 @default.
• W4225142419 hasAuthorship W4225142419A5034598092 @default.
• W4225142419 hasAuthorship W4225142419A5049560724 @default.
• W4225142419 hasAuthorship W4225142419A5053296449 @default.
• W4225142419 hasAuthorship W4225142419A5067132709 @default.
• W4225142419 hasAuthorship W4225142419A5073825416 @default.
• W4225142419 hasBestOaLocation W42251424192 @default.
• W4225142419 hasConcept C126322002 @default.
• W4225142419 hasConcept C131872663 @default.
• W4225142419 hasConcept C141071460 @default.
• W4225142419 hasConcept C167135981 @default.
• W4225142419 hasConcept C172680121 @default.
• W4225142419 hasConcept C187212893 @default.
• W4225142419 hasConcept C203014093 @default.
• W4225142419 hasConcept C2776689292 @default.
• W4225142419 hasConcept C2779234561 @default.
• W4225142419 hasConcept C2779989375 @default.
• W4225142419 hasConcept C44249647 @default.
• W4225142419 hasConcept C54355233 @default.
• W4225142419 hasConcept C71924100 @default.
• W4225142419 hasConcept C82789193 @default.
• W4225142419 hasConcept C86803240 @default.
• W4225142419 hasConcept C89560881 @default.
• W4225142419 hasConceptScore W4225142419C126322002 @default.
• W4225142419 hasConceptScore W4225142419C131872663 @default.
• W4225142419 hasConceptScore W4225142419C141071460 @default.
• W4225142419 hasConceptScore W4225142419C167135981 @default.
• W4225142419 hasConceptScore W4225142419C172680121 @default.
• W4225142419 hasConceptScore W4225142419C187212893 @default.
• W4225142419 hasConceptScore W4225142419C203014093 @default.
• W4225142419 hasConceptScore W4225142419C2776689292 @default.
• W4225142419 hasConceptScore W4225142419C2779234561 @default.
• W4225142419 hasConceptScore W4225142419C2779989375 @default.
• W4225142419 hasConceptScore W4225142419C44249647 @default.
• W4225142419 hasConceptScore W4225142419C54355233 @default.

• next